Falecalcitriol - CAS 83805-11-2
Catalog number: 83805-11-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C27H38F6O3
Molecular Weight:
524.58
COA:
Inquire
Targets:
VD/VDR
Description:
Falecalcitriol is an analog of calcitriol. It has a higher potency both in vivo and in vitro systems, and longer duration of action in vivo.
Purity:
>98%
Synonyms:
Ro 23-4194; Ro-23-4194; Ro23-4194; ST 630; ST-630; ST630; Flocalcitriol; Hornel, Fulstan; Falecalcitriol.
MSDS:
Inquire
InChIKey:
XPYGGHVSFMUHLH-UUSULHAXSA-N
InChI:
InChI=1S/C27H38F6O3/c1-16(6-4-13-25(36,26(28,29)30)27(31,32)33)21-10-11-22-18(7-5-12-24(21,22)3)8-9-19-14-20(34)15-23(35)17(19)2/h8-9,16,20-23,34-36H,2,4-7,10-15H2,1,3H3/b18-8+,19-9-/t16-,20-,21-,22+,23+,24-/m1/s1
Canonical SMILES:
CC(CCCC(C(F)(F)F)(C(F)(F)F)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C
1.Vitamin D analogs for secondary hyperparathyroidism: what does the future hold?
Brown AJ1. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):578-83. Epub 2006 Dec 27.
Secondary hyperparathyroidism (2 degrees HPT) commonly develops in patients with chronic kidney disease (CKD) in response to high phosphate, low calcium and low 1,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)]. High PTH levels increase the rate of bone turnover, with a net efflux of calcium and phosphate leading to vascular calcification and coronary artery disease. Treatment of 2 degrees HPT with 1alpha,25(OH)(2)D(3) and calcium-based phosphate binders often produces hypercalcemia and over-suppression of PTH, resulting in adynamic bone that cannot buffer excess calcium and phosphate, which increases the risk of vascular calcification. It is essential, then, to reduce PTH levels to a range that supports normal bone turnover and minimizes ectopic calcification. Vitamin D analogs that inhibit PTH gene transcription and parathyroid hyperplasia, and that have less calcemic activity than 1alpha,25(OH)(2)D(3,) have provided a greater safety margin for the treatment of 2 degrees HPT, as well as enhancing the survival of CKD patients.
2.[Long-term suppressive effect of falecalcitriol on parathyroid hormone secretion in secondary hyperparathyroidism in hemodialysis patients].
Iwao Y1, Yamaguchi Y, Fujii K, Toba Y, Asada M, Nagano N, Yamamoto H, Hyoma K, Yamada S, Hirano H, Tone Y, Ohtani H, Saika Y, Fujii R. Clin Calcium. 2006 May;16(5):847-51.
Alfacarcidol and calcitriol are widely used to treat secondary hyperparathyroidism associated with chronic renal failure, but it is often not possible to administer doses high enough to sufficiently inhibit parathyroid hormones because of the risk of hypercalcemia and hyperphosphatemia. We administered falecalcitriol (Hornel) Tablets) to patients with poorly controlled secondary hyperparathyroidism. The usefulness of falecalcitriol was demonstrated by the fact that control of intact-PTH was maintained for up to 24 months without a clear increase in serum Ca x serum inorganic phosphorus (iP), iP, and ALP levels.
3.Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR. Methods Find Exp Clin Pharmacol. 2005 Apr;27(3):193-219.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity. prous.com. This issue focuses on the following selection of drugs: ABX-IL-8, Acclaim, adalimumab, AGI-1067, alagebrium chloride, alemtuzumab, Alequel, Androgel, anti-IL-12 MAb, AOD-9604, aripiprazole, atomoxetine hydrochloride; Biphasic insulin aspart, bosentan, botulinum toxin type B, bovine lactoferrin, brivudine; Cantuzumab mertansine, CB-1954, CDB-4124, CEA-TRICOM, choriogonadotropin alfa, cilansetron, CpG-10101, CpG-7909, CTL-102, CTL-102/CB-1954; DAC:GRF, darbepoetin alfa, davanat-1, decitabine, del-1 Genemedicine, dexanabinol, dextofisopam, dnaJP1, dronedarone hydrochloride, dutasteride; Ecogramostim, eletriptan, emtricitabine, EPI-hNE-4, eplerenone, eplivanserin fumarate, erlotinib hydrochloride, ertapenem sodium, escitalopram oxalate, esomeprazole magnesium, etoricoxib, ezetimibe; Falecalcitriol, fingolimod hydrochloride; Gepirone hydrochloride; HBV-ISS, HSV-2 theracine, human insulin; Imatinib mesylate, Indiplon, insulin glargine, ISAtx-247; L612 HuMAb, levodopa/carbidopa/entacapone, lidocaine/prilocaine, LL-2113AD, lucinactant, LY-156735; Meclinertant, metelimumab, morphine hydrochloride, morphine-6-glucuronide; Natalizumab, nimotuzumab, NX-1207, NYVAC-HIV C; Omalizumab, onercept, osanetant; PABA, palosuran sulfate, parathyroid hormone (human recombinant), parecoxib sodium, PBI-1402, PCK-3145, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pemetrexed disodium, pimecrolimus, PINC, pregabalin; Ramelteon, rasagiline mesilate, rasburicase, rimonabant hydrochloride, RO-0098557, rofecoxib, rosiglitazone maleate/metformin hydrochloride; Safinamide mesilate, SHL-749, sitaxsentan sodium, sparfosic acid, SprayGel, squalamine, St.
4.Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
Ito H1, Ogata H, Yamamoto M, Takahashi K, Shishido K, Takahashi J, Taguchi S, Kinugasa E. Clin Nephrol. 2009 Jun;71(6):660-8.
BACKGROUND: Falecalcitriol is a novel vitamin D analog, which has a greater potential to suppress parathyroid hormone (PTH) and a longer half-life. There are few studies to compare clinical effects of oral falecalcitriol treatment with those of intravenous calcitriol treatment.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related VD/VDR Products


CAS 131875-08-6 Lexacalcitol

Lexacalcitol
(CAS: 131875-08-6)

KH1060 metabolism could be blocked by the cytochrome P450 inhibitor, ketoconazole. KH1060 was not an effective competitor of C24 oxidation of 1alpha,25-(OH)2D3....

CAS 113082-99-8 Calcipotriol Impurity C

Calcipotriol Impurity C
(CAS: 113082-99-8)

Calcipotriol Impurity C, the trans-isomeric impurity of Calcipotriene, is an analogue of VD3 which could be an agonist of vitamin D receptor.

CAS 55700-58-8 (24S)-24,25-Dihydroxyvitamin D3

(24S)-24,25-Dihydroxyvitamin D3
(CAS: 55700-58-8)

(24S)-24,25-Dihydroxycholecalciferol is an inactive form of vitamin D3 which undergoes various levels of hydroxylation to form active vitamin D3 analogs.

CAS 32222-06-3 Calcitriol

Calcitriol
(CAS: 32222-06-3)

Calcitriol is the hormonally active form of vitamin D.

CAS 112828-09-8 (24R)-MC 976

(24R)-MC 976
(CAS: 112828-09-8)

(24R)-MC 976 is a Vitamin D3 derivative.

CAS 134404-52-7 Seocalcitol

Seocalcitol
(CAS: 134404-52-7)

Seocalcitol is a vitamin D receptor (VDR) agonist. Seocalcitol exhibits anti-tumor and anti-proliferative activity with reduced hypercalcemic effects

CAS 19356-17-3 Calcifediol

Calcifediol
(CAS: 19356-17-3)

Calcifediol is a major circulating metabolite of vitamin D3 and acts as a competitive inhibitor with an apparent Ki of 3.9 μM. It also suppresses PTH secretion ...

CAS 40013-87-4 24, 25-Dihydroxy VD3

24, 25-Dihydroxy VD3
(CAS: 40013-87-4)

24, 25-Dihydroxy VD3 is a compound which is closely related to 1,25-dihydroxyvitamin D3, the active form of vitamin D3, but like vitamin D3 itself and 25-hydrox...

Chemical Structure

CAS 83805-11-2 Falecalcitriol

Quick Inquiry

Verification code

Featured Items